Quantum-Si is a thinly covered life-sciences company, and the small number of published targets is itself part of the story. For this article, three current, attributable targets were reviewed. H.C. Wainwright's Swayampakula Ramakanth reiterated a Buy rating with a $4.00 target in August 2026. Alliance Global Partners' Scott Henry kept a Buy rating but cut his target to $1.90 from $2.50 following the company's second-quarter report. Canaccord Genuity reiterated a Hold rating with a $1.00 target in May 2026.
The arithmetic mean of these three figures is about $2.30, which is the rounded central target used here. It is not an officially published consensus. The low-to-high spread of $1.00 to $4.00 is unusually wide, which signals that analysts are pricing in very different assumptions about whether Quantum-Si can convert its technology into commercial traction. The two Buy-rated analysts see meaningful upside from the Proteus platform, while the Hold-rated view reflects skepticism about near-term commercialization and revenue.
Quantum-Si shares recently closed near $1.65, after a sharp rally that lifted the stock well off its 52-week low of roughly $0.69. A move to $2.30 implies upside of about 39%, which should be characterized as substantial given the company's limited revenue and history of losses.
The path toward that level would likely depend on progress with Proteus, the company's next-generation single-molecule protein-sequencing platform. Management has described a controlled-to-commercial launch transition, but the Proteus rollout has been delayed, extending the period before meaningful recurring revenue can scale. In the meantime, revenue remains tiny — roughly $344,000 in the most recent reported quarter — against a much larger cost base, so any sustained re-rating toward the target would require visible commercial milestones rather than valuation expansion alone.
The primary support is the Proteus platform and the broader proteomics opportunity. Quantum-Si aims to make protein sequencing more accessible and affordable, and successful demonstrations — including progress toward identifying all 20 standard amino acids — have at times driven sharp rallies in the shares. Management has also moved to conserve cash, including a workforce reduction, and has signaled an extended runway into late 2028, reducing near-term financing pressure.
Analyst support matters here as well. Two of the three tracked analysts maintain Buy ratings, and their targets sit well above the current price. If Proteus gains customer traction or if the company announces new partnerships or placements, sentiment could improve quickly, particularly given the stock's high beta and its tendency to trade on news and momentum.
The risks are substantial. Revenue has declined sharply year over year, and the company remains deeply unprofitable on both a GAAP and operating basis. The Proteus launch delay postpones customer evaluations and consumables pull-through, meaning losses could persist well into the future. Quantum-Si is not a quantum-computing business, and some of its recent share-price strength has been tied to investor confusion around that theme, which could unwind.
There is also a Nasdaq minimum bid-price compliance risk; failure to regain compliance could lead to delisting or corporate actions such as a reverse stock split. A future capital raise or secondary offering would also pressure the share price, and insider selling activity has been reported. Any of these factors could keep the stock well below $2.30.
The stock's long-term range tells a story of extreme volatility. Shares have traded from about $0.69 on the low side to the low $2.30s on the high side over the past year. The recent advance has lifted the stock back toward the $2.00 psychological zone, with prior highs in the $2.32-to-$2.42 area acting as the next notable resistance. On the downside, the area near the last closing level around $1.46 and the $1.00 mark represent reference support zones. Because the stock is highly volatile, these levels should be viewed as broad zones rather than precise turning points.
Analyst price targets typically reflect a research horizon of roughly 12 months, though the three firms here do not publish identical timelines and one target predates the others. Investors should watch the next quarterly earnings report, expected in early November 2026, along with any updates on Proteus launch timing, customer placements, and consumables revenue. Cost discipline and cash-burn figures will matter, as will any announcement about Nasdaq compliance or future financing. Changes to analyst targets or ratings — particularly any revisions from the two Buy-rated firms — would also be a key signal.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a volatile, event-driven name like Quantum-Si, such tools can help traders surface opportunities, track positions, and spot changing trends more efficiently than manual chart review alone. Traders looking for a data-driven edge may want to explore how these signals complement their own research.
The $2.30 figure is a calculated average of three analyst targets, not a forecast of what will happen. Reaching it would require a roughly 39% advance from around $1.65 — a substantial move that hinges largely on the Proteus platform gaining real commercial traction. The wide $1.00-to-$4.00 target range shows that analysts genuinely disagree about that outcome. Support comes from the platform's potential, an extended cash runway, and two Buy ratings; obstacles include a delayed launch, shrinking revenue, persistent losses, and listing-compliance risk. Investors should watch Proteus milestones, the upcoming earnings report, and any analyst or financing developments before drawing conclusions.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, QSI has been loosely correlated with AXON. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if QSI jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To QSI | 1D Price Change % | ||
|---|---|---|---|---|
| QSI | 100% | +13.68% | ||
| AXON - QSI | 49% Loosely correlated | -18.18% | ||
| PACB - QSI | 47% Loosely correlated | -7.20% | ||
| VCYT - QSI | 47% Loosely correlated | +0.67% | ||
| MASS - QSI | 41% Loosely correlated | +4.04% | ||
| TXG - QSI | 41% Loosely correlated | +2.10% | ||
More | ||||
| Ticker / NAME | Correlation To QSI | 1D Price Change % |
|---|---|---|
| QSI | 100% | +13.68% |
| Medical/Nursing Services industry (138 stocks) | 1% Poorly correlated | +49.28% |
| Health Services industry (239 stocks) | 1% Poorly correlated | +29.61% |